Silence Therapeutics PLC Update on Litigation Matters (4621V)
03 November 2017 - 6:00PM
UK Regulatory
TIDMSLN
RNS Number : 4621V
Silence Therapeutics PLC
03 November 2017
Update on litigation matters
3 November 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces an update on litigation matters.
Previously, the Company delivered its claim for declaratory relief
relating to its entitlement to Supplementary Protection
Certificates (SPCs) on certain Alnylam products, naming as
defendants Alnylam UK Limited, Alnylam Pharmaceuticals Inc, and The
Medicines Company UK Limited.
Alnylam UK Limited and The Medicines Company UK Limited have
sued to revoke the relevant Silence European patent in the UK, and
also included claims for declarations of non-infringement of this
European patent by certain Alnylam products.
Silence regards the actions taken by the defendants as simply
"normal course of business" at the commencement of litigation, and
continues to believe that certain Alnylam products require a
licence under the Silence patent estate.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"During 2017, both the European and US patent offices have
continued to uphold the validity of our expanding patent estate
with the granting of additional patents. We believe that our
fundamental chemical modification technology is core foundational
innovation for today's RNAi sector, and that therefore those
companies using such modification technology within the scope of
our Intellectual Property (IP) will require a licence. Silence is
committed to defending its position and to securing the appropriate
recognition and associated value for its IP."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20
and Broker) 7418 8900
James Steel/Oliver Jackson
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDUGGUGGUPMPPP
(END) Dow Jones Newswires
November 03, 2017 03:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024